Impact BioMedical Inc(IBO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.1 | Insider Own | 0.46% | Shs Outstand | 107.8M | Perf Week | -10% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | -16.08% | Shs Float | 107.3M | Perf Month | 2.56% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 3.56% | Short Float | 0.51% | Perf Quarter | -22.5% |
| Income | 0.00B | P/S | 1188.7 | EPS this Y | - | Inst Trans | 0.19% | Short Ratio | 4.87 | Perf Half Y | -19.82% |
| Sales | 0.00B | P/B | 4.42 | EPS next 5Y | - | ROA | 4.41% | Short Interest | 0.55M | Perf YTD | -12.67% |
| Book/sh | 0.1 | P/C | 4754.8 | EPS past 3/5Y | 15.09% -48.53% | ROE | 371.29% | 52W High | -46.87% ($0.83) | Perf Year | -31.84% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 7.33% | 52W Low | 19.19% ($0.37) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 97% | Gross Margin | -4377.14% | Volatility(W/M) | 11.86% 8.34% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1269.7 | Sales Y/Y TTM | 400% | Oper. Margin | -14562.86% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.13 | EPS Q/Q | 99.45% | Profit Margin | 2254.29% | RSI (14) | 45.29 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.16 | Sales Q/Q | -57.14% | SMA20 | -5.27% ($0.46) | Beta | 2.66 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -2.86% ($0.45) | Rel Volume | 2.29 | Prev Close | $0.49 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -14.28% ($0.51) | Avg Volume(3M) | 0.11M | Price | $0.44 |
| IPO | 2024/9/16 | Option/Short | No/Yes | Trades | 263 | Volume | 257,504 | Change | -10.67% |
Company
IBO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. intellectual property (IP)-drivn biotech company that targets cancer, infectious diseases, and metabolic disorders through plant-based functional materials and a novel drug platform. Leveraging its proprietary antimicrobial technology and small-molecule compounds, the company is pursuing commercialization through global partnerships.
Over the past 1 year, on the lower side
47% below its 1-year high.
IBO has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 3.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ITOT 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $48M.
IBO $48M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is IBO?
IBO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IBO?
The market cap of IBO is approximately $48M, ranking 4,963 within its sector.
What is the 52-week high and low for IBO?
IBO has recorded a 52-week high of $0.83 and a low of $0.37.
